Upcoming Dividend • May 21
Upcoming dividend of JP¥37.50 per share Eligible shareholders must have bought the stock before 28 May 2026. Payment date: 04 August 2026. Payout ratio is a comfortable 19% but the company is not cash flow positive. Trailing yield: 1.2%. Lower than top quartile of Japanese dividend payers (3.8%). Lower than average of industry peers (2.0%). Duyuru • May 09
COSMOS Pharmaceutical Corporation to Report Fiscal Year 2026 Results on Jul 13, 2026 COSMOS Pharmaceutical Corporation announced that they will report fiscal year 2026 results on Jul 13, 2026 Reported Earnings • Apr 14
Third quarter 2026 earnings: EPS and revenues exceed analyst expectations Third quarter 2026 results: EPS: JP¥102 (up from JP¥99.87 in 3Q 2025). Revenue: JP¥273.2b (up 11% from 3Q 2025). Net income: JP¥8.10b (up 2.3% from 3Q 2025). Profit margin: 3.0% (down from 3.2% in 3Q 2025). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.7%. Earnings per share (EPS) also surpassed analyst estimates by 1.5%. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Duyuru • Apr 03
COSMOS Pharmaceutical Corporation to Report Q3, 2026 Results on Apr 13, 2026 COSMOS Pharmaceutical Corporation announced that they will report Q3, 2026 results on Apr 13, 2026 Declared Dividend • Feb 13
First half dividend of JP¥37.50 announced Shareholders will receive a dividend of JP¥37.50. Ex-date: 28th May 2026 Payment date: 4th August 2026 Dividend yield will be 1.0%, which is lower than the industry average of 1.6%. Sustainability & Growth Dividend is covered by earnings (19% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 17% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 19% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Jan 14
Second quarter 2026 earnings: EPS misses analyst expectations Second quarter 2026 results: EPS: JP¥81.72 (up from JP¥79.30 in 2Q 2025). Revenue: JP¥264.8b (up 8.5% from 2Q 2025). Net income: JP¥6.48b (up 3.1% from 2Q 2025). Profit margin: 2.4% (down from 2.6% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 2.7%. Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Duyuru • Jan 14
Cosmos Pharmaceutical Corporation Announces Dividend for the Second Quarter-End of the Fiscal Year Ending May 31, 2026, Payable on February 12, 2026 COSMOS Pharmaceutical Corporation announced dividend of JPY 37.50 per share for the second quarter-end of the fiscal year ending May 31, 2026 against JPY 32.50 per share paid a year ago. Scheduled date of commencing dividend payments is February 12, 2026. Upcoming Dividend • Nov 20
Upcoming dividend of JP¥37.50 per share Eligible shareholders must have bought the stock before 27 November 2025. Payment date: 12 February 2026. Payout ratio is a comfortable 18% but the company is not cash flow positive. Trailing yield: 1.0%. Lower than top quartile of Japanese dividend payers (3.7%). Lower than average of industry peers (1.5%). Duyuru • Nov 05
COSMOS Pharmaceutical Corporation to Report Q2, 2026 Results on Jan 13, 2026 COSMOS Pharmaceutical Corporation announced that they will report Q2, 2026 results on Jan 13, 2026 Reported Earnings • Oct 15
First quarter 2026 earnings: EPS misses analyst expectations First quarter 2026 results: EPS: JP¥103 (up from JP¥103 in 1Q 2025). Revenue: JP¥272.4b (up 4.0% from 1Q 2025). Net income: JP¥8.17b (flat on 1Q 2025). Profit margin: 3.0% (down from 3.1% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.0%. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Declared Dividend • Sep 08
Final dividend of JP¥37.50 announced Shareholders will receive a dividend of JP¥37.50. Ex-date: 27th November 2025 Payment date: 12th February 2026 Dividend yield will be 0.8%, which is lower than the industry average of 1.6%. Reported Earnings • Sep 02
Full year 2025 earnings: Revenues and EPS in line with analyst expectations Full year 2025 results: EPS: JP¥391 (up from JP¥309 in FY 2024). Revenue: JP¥1.01t (up 4.8% from FY 2024). Net income: JP¥31.0b (up 27% from FY 2024). Profit margin: 3.1% (up from 2.5% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 7% per year. Duyuru • Jul 30
COSMOS Pharmaceutical Corporation to Report Q1, 2026 Results on Oct 14, 2025 COSMOS Pharmaceutical Corporation announced that they will report Q1, 2026 results on Oct 14, 2025 Reported Earnings • Jul 14
Full year 2025 earnings: Revenues and EPS in line with analyst expectations Full year 2025 results: EPS: JP¥391 (up from JP¥309 in FY 2024). Revenue: JP¥1.01t (up 4.8% from FY 2024). Net income: JP¥31.0b (up 27% from FY 2024). Profit margin: 3.1% (up from 2.5% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 1.9% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 8% per year. Duyuru • Jul 11
COSMOS Pharmaceutical Corporation, Annual General Meeting, Aug 21, 2025 COSMOS Pharmaceutical Corporation, Annual General Meeting, Aug 21, 2025. Upcoming Dividend • May 22
Upcoming dividend of JP¥32.50 per share Eligible shareholders must have bought the stock before 29 May 2025. Payment date: 01 August 2025. Payout ratio is a comfortable 17% but the company is paying out more than the cash it is generating. Trailing yield: 0.7%. Lower than top quartile of Japanese dividend payers (4.0%). Lower than average of industry peers (1.7%). Duyuru • May 01
COSMOS Pharmaceutical Corporation to Report Fiscal Year 2025 Results on Jul 11, 2025 COSMOS Pharmaceutical Corporation announced that they will report fiscal year 2025 results on Jul 11, 2025 Reported Earnings • Apr 15
Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2025 results: EPS: JP¥99.87 (up from JP¥72.80 in 3Q 2024). Revenue: JP¥246.3b (up 3.1% from 3Q 2024). Net income: JP¥7.92b (up 37% from 3Q 2024). Profit margin: 3.2% (up from 2.4% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) exceeded analyst estimates by 31%. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 12% per year. Declared Dividend • Feb 13
First half dividend of JP¥32.50 announced Shareholders will receive a dividend of JP¥32.50. Ex-date: 29th May 2025 Payment date: 1st August 2025 Dividend yield will be 0.9%, which is lower than the industry average of 1.6%. Payout Ratios Payout ratio: 18%. Cash payout ratio: 146%. Duyuru • Feb 03
COSMOS Pharmaceutical Corporation to Report Q3, 2025 Results on Apr 11, 2025 COSMOS Pharmaceutical Corporation announced that they will report Q3, 2025 results on Apr 11, 2025 Reported Earnings • Jan 15
Second quarter 2025 earnings: EPS exceeds analyst expectations Second quarter 2025 results: EPS: JP¥79.30 (up from JP¥64.09 in 2Q 2024). Revenue: JP¥244.1b (up 4.0% from 2Q 2024). Net income: JP¥6.29b (up 24% from 2Q 2024). Profit margin: 2.6% (up from 2.2% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 25%. Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 4% per year whereas the company’s share price has remained flat. Duyuru • Jan 10
Cosmos Pharmaceutical Corporation Announces Dividend for the Second Quarter-End of Fiscal Year Ending May 31, 2025, Payable on February 12, 2025 COSMOS Pharmaceutical Corporation announced dividend of JPY 32.50 per share for the second quarter-end of fiscal year ending May 31, 2025 compared to JPY 60.00 per share paid a year ago. Scheduled date of commencing dividend payments: February 12, 2025. Upcoming Dividend • Nov 21
Upcoming dividend of JP¥32.50 per share Eligible shareholders must have bought the stock before 28 November 2024. Payment date: 13 February 2025. Payout ratio is a comfortable 18% but the company is not cash flow positive. Trailing yield: 1.0%. Lower than top quartile of Japanese dividend payers (3.8%). Lower than average of industry peers (1.6%). Duyuru • Oct 29
COSMOS Pharmaceutical Corporation to Report Q2, 2025 Results on Jan 10, 2025 COSMOS Pharmaceutical Corporation announced that they will report Q2, 2025 results on Jan 10, 2025 Reported Earnings • Oct 13
First quarter 2025 earnings: EPS exceeds analyst expectations First quarter 2025 results: EPS: JP¥103 (up from JP¥82.17 in 1Q 2024). Revenue: JP¥261.8b (up 8.4% from 1Q 2024). Net income: JP¥8.14b (up 25% from 1Q 2024). Profit margin: 3.1% (up from 2.7% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 16%. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Price Target Changed • Oct 12
Price target increased by 7.0% to JP¥8,198 Up from JP¥7,660, the current price target is an average from 13 analysts. New target price is 12% above last closing price of JP¥7,320. Stock is up 5.9% over the past year. The company is forecast to post earnings per share of JP¥335 for next year compared to JP¥309 last year. Declared Dividend • Sep 19
Final dividend of JP¥32.50 announced Shareholders will receive a dividend of JP¥32.50. Ex-date: 28th November 2024 Payment date: 13th February 2025 Dividend yield will be 1.3%, which is lower than the industry average of 1.6%. Duyuru • Aug 09
COSMOS Pharmaceutical Corporation to Report Q1, 2025 Results on Oct 11, 2024 COSMOS Pharmaceutical Corporation announced that they will report Q1, 2025 results on Oct 11, 2024 Reported Earnings • Jul 14
Full year 2024 earnings: EPS misses analyst expectations Full year 2024 results: EPS: JP¥617 (up from JP¥601 in FY 2023). Revenue: JP¥965.0b (up 17% from FY 2023). Net income: JP¥24.5b (up 2.8% from FY 2023). Profit margin: 2.5% (down from 2.9% in FY 2023). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 2.4%. Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 10% per year, which means it is performing significantly worse than earnings. Duyuru • Jul 13
COSMOS Pharmaceutical Corporation, Annual General Meeting, Aug 20, 2024 COSMOS Pharmaceutical Corporation, Annual General Meeting, Aug 20, 2024. Upcoming Dividend • May 23
Upcoming dividend of JP¥60.00 per share Eligible shareholders must have bought the stock before 30 May 2024. Payment date: 05 August 2024. Payout ratio is a comfortable 9.2% but the company is paying out more than the cash it is generating. Trailing yield: 0.9%. Lower than top quartile of Japanese dividend payers (3.4%). Lower than average of industry peers (1.7%). Reported Earnings • Apr 14
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Third quarter 2024 results: EPS: JP¥146 (up from JP¥126 in 3Q 2023). Revenue: JP¥238.9b (up 18% from 3Q 2023). Net income: JP¥5.77b (up 16% from 3Q 2023). Profit margin: 2.4% (down from 2.5% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.7%. Earnings per share (EPS) also surpassed analyst estimates by 7.5%. Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has fallen by 4% per year and the company’s share price has also fallen by 4% per year. Duyuru • Jan 31
COSMOS Pharmaceutical Corporation to Report Q3, 2024 Results on Apr 12, 2024 COSMOS Pharmaceutical Corporation announced that they will report Q3, 2024 results on Apr 12, 2024 Reported Earnings • Jan 14
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Second quarter 2024 results: EPS: JP¥128 (up from JP¥122 in 2Q 2023). Revenue: JP¥234.8b (up 19% from 2Q 2023). Net income: JP¥5.08b (up 5.4% from 2Q 2023). Profit margin: 2.2% (down from 2.4% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) also surpassed analyst estimates by 3.9%. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 2.8% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has remained flat. Upcoming Dividend • Nov 22
Upcoming dividend of JP¥60.00 per share at 0.8% yield Eligible shareholders must have bought the stock before 29 November 2023. Payment date: 13 February 2024. Payout ratio is a comfortable 17% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of Japanese dividend payers (3.4%). Lower than average of industry peers (1.7%). Duyuru • Nov 01
COSMOS Pharmaceutical Corporation to Report Q2, 2024 Results on Jan 12, 2024 COSMOS Pharmaceutical Corporation announced that they will report Q2, 2024 results on Jan 12, 2024 Reported Earnings • Oct 12
First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2024 results: EPS: JP¥164 (up from JP¥164 in 1Q 2023). Revenue: JP¥241.7b (up 17% from 1Q 2023). Net income: JP¥6.51b (flat on 1Q 2023). Profit margin: 2.7% (down from 3.1% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) missed analyst estimates by 1.4%. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 6% per year. Duyuru • Oct 11
COSMOS Pharmaceutical Corporation Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending May 31, 2024 COSMOS Pharmaceutical Corporation provided consolidated earnings guidance for the first half and full year of fiscal year ending May 31, 2024. For the first half, the company expects net sales of JPY 450,400 million, operating profit of JPY 14,100 million, profit attributable to owners of parent of JPY 10,577 million and basic earnings per share of JPY 267.10.For the full year, the company expects net sales of JPY 916,000 million, operating profit of JPY 30,200 million, profit attributable to owners of parent of JPY 23,800 million and basic earnings per share of JPY 601.03. Reported Earnings • Sep 05
Full year 2023 earnings: EPS exceeds analyst expectations Full year 2023 results: EPS: JP¥601 (up from JP¥585 in FY 2022). Revenue: JP¥827.7b (up 9.6% from FY 2022). Net income: JP¥23.8b (up 2.8% from FY 2022). Profit margin: 2.9% (down from 3.1% in FY 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.4%. Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 2.4% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 1% per year. Duyuru • Aug 03
COSMOS Pharmaceutical Corporation to Report Q1, 2024 Results on Oct 11, 2023 COSMOS Pharmaceutical Corporation announced that they will report Q1, 2024 results on Oct 11, 2023 Reported Earnings • Jul 16
Full year 2023 earnings: EPS exceeds analyst expectations Full year 2023 results: EPS: JP¥601 (up from JP¥585 in FY 2022). Revenue: JP¥827.7b (up 9.6% from FY 2022). Net income: JP¥23.8b (up 2.8% from FY 2022). Profit margin: 2.9% (down from 3.1% in FY 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.4%. Revenue is forecast to grow 8.0% p.a. on average during the next 3 years, compared to a 2.3% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 6% per year. Upcoming Dividend • May 23
Upcoming dividend of JP¥42.50 per share at 0.6% yield Eligible shareholders must have bought the stock before 30 May 2023. Payment date: 24 August 2023. Payout ratio is a comfortable 14% but the company is not cash flow positive. Trailing yield: 0.6%. Lower than top quartile of Japanese dividend payers (3.5%). Lower than average of industry peers (1.6%). Reported Earnings • Apr 11
Third quarter 2023 earnings: EPS misses analyst expectations Third quarter 2023 results: EPS: JP¥126 (down from JP¥132 in 3Q 2022). Revenue: JP¥202.3b (up 7.7% from 3Q 2022). Net income: JP¥4.98b (down 4.3% from 3Q 2022). Profit margin: 2.5% (down from 2.8% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 9.9%. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 1.8% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 4% per year. Duyuru • Feb 09
COSMOS Pharmaceutical Corporation to Report Q3, 2023 Results on Apr 10, 2023 COSMOS Pharmaceutical Corporation announced that they will report Q3, 2023 results on Apr 10, 2023 Reported Earnings • Jan 14
Second quarter 2023 earnings: EPS misses analyst expectations Second quarter 2023 results: EPS: JP¥122 (down from JP¥126 in 2Q 2022). Revenue: JP¥197.9b (up 8.9% from 2Q 2022). Net income: JP¥4.82b (down 3.7% from 2Q 2022). Profit margin: 2.4% (down from 2.8% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 7.9%. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 2.1% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 4% per year whereas the company’s share price has increased by 3% per year. Duyuru • Jan 14
Cosmos Pharmaceutical Corporation Provides Earnings Forecast for the Fiscal Year Ending May 31, 2023 COSMOS Pharmaceutical Corporation provided earnings Forecast for the Fiscal Year Ending May 31, 2023. For the period, The company expects Net sales of JPY 813,500 million. Operating profit of JPY 30,000 million. Profit attributable to owners of parent of JPY 23,200 million. Basic earnings per share of JPY 585.87. Upcoming Dividend • Nov 22
Upcoming dividend of JP¥42.50 per share Eligible shareholders must have bought the stock before 29 November 2022. Payment date: 14 February 2023. Payout ratio is a comfortable 14% but the company is not cash flow positive. Trailing yield: 0.6%. Lower than top quartile of Japanese dividend payers (3.7%). Lower than average of industry peers (1.6%). Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 6 highly experienced directors. No independent directors (10 non-independent directors). External Director Masao Ueda was the last director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Duyuru • Oct 30
COSMOS Pharmaceutical Corporation to Report Q2, 2023 Results on Jan 12, 2023 COSMOS Pharmaceutical Corporation announced that they will report Q2, 2023 results on Jan 12, 2023 Reported Earnings • Oct 13
First quarter 2023 earnings: EPS exceeds analyst expectations First quarter 2023 results: EPS: JP¥164 (up from JP¥158 in 1Q 2022). Revenue: JP¥206.1b (up 8.8% from 1Q 2022). Net income: JP¥6.48b (up 3.8% from 1Q 2022). Profit margin: 3.1% (down from 3.3% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.0%. Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 11% per year. Duyuru • Oct 11
COSMOS Pharmaceutical Corporation Provides Dividend Guidance for the Second Quarter-End and Full Year of Fiscal Year Ending May 31, 2023 COSMOS Pharmaceutical Corporation provided dividend guidance for the second quarter-end and full year of fiscal year ending May 31, 2023. For the second quarter-end, the company expects to pay dividend of JPY 42.50 per share against JPY 40.00 per share paid for the same period a year ago.For the full year, the company expects to pay year-end dividend of JPY 42.50 per share against JPY 40.00 per share paid for the same period a year ago. Reported Earnings • Sep 04
Full year 2022 earnings: EPS exceeds analyst expectations Full year 2022 results: EPS: JP¥585 (down from JP¥686 in FY 2021). Revenue: JP¥755.4b (up 4.0% from FY 2021). Net income: JP¥23.2b (down 15% from FY 2021). Profit margin: 3.1% (down from 3.7% in FY 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.4%. Over the next year, revenue is forecast to grow 8.6%, compared to a 11% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 12% per year. Duyuru • Aug 18
COSMOS Pharmaceutical Corporation to Report Q1, 2023 Results on Oct 11, 2022 COSMOS Pharmaceutical Corporation announced that they will report Q1, 2023 results on Oct 11, 2022 Duyuru • Jul 13
COSMOS Pharmaceutical Corporation, Annual General Meeting, Aug 23, 2022 COSMOS Pharmaceutical Corporation, Annual General Meeting, Aug 23, 2022. Reported Earnings • Jul 13
Full year 2022 earnings: EPS exceeds analyst expectations Full year 2022 results: EPS: JP¥585 (down from JP¥686 in FY 2021). Revenue: JP¥755.4b (up 4.0% from FY 2021). Net income: JP¥23.2b (down 15% from FY 2021). Profit margin: 3.1% (down from 3.7% in FY 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.4%. Over the next year, revenue is forecast to grow 8.9%, compared to a 18% growth forecast for the retail industry in Japan. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 10% per year. Duyuru • Jul 12
COSMOS Pharmaceutical Corporation Announces Dividend Guidance for the Second Quarter and Year End of Fiscal Year Ending May 31, 2023 COSMOS Pharmaceutical Corporation announced dividend guidance for the second quarter and year end of fiscal year ending May 31, 2023. FOr the quarter, the company expected dividend of JPY 42.50 per share.FOr the year, the company expected dividend of JPY 42.50 per share. Price Target Changed • Jun 15
Price target decreased to JP¥14,800 Down from JP¥16,100, the current price target is an average from 11 analysts. New target price is 28% above last closing price of JP¥11,580. Stock is down 30% over the past year. The company is forecast to post earnings per share of JP¥581 for next year compared to JP¥686 last year. Upcoming Dividend • May 23
Upcoming dividend of JP¥40.00 per share Eligible shareholders must have bought the stock before 30 May 2022. Payment date: 25 August 2022. Payout ratio is a comfortable 15% but the company is not cash flow positive. Trailing yield: 0.7%. Lower than top quartile of Japanese dividend payers (3.7%). Lower than average of industry peers (1.8%). Duyuru • May 12
COSMOS Pharmaceutical Corporation to Report Fiscal Year 2022 Results on Jul 11, 2022 COSMOS Pharmaceutical Corporation announced that they will report fiscal year 2022 results on Jul 11, 2022 Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 6 highly experienced directors. No independent directors (10 non-independent directors). External Director Masao Ueda was the last director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. 
